| Featured Story | By Ben Adams Johnson & Johnson is walking away from a $1.6 billion biobucks blood cancer med deal with Belgium’s argenx for the CD70-targeting cusatuzumab. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus The FDA lifted a clinical hold it placed on bluebird bio’s sickle cell gene therapy in February, making way for the company to get a phase 1/2 trial and phase 3 study of the treatment back on track. Bluebird paused the trials in mid-February after two patients in the phase 1/2 study developed blood cancer after treatment. read more By Annalee Armstrong You’d think Amgen would still be celebrating in the halls after scoring an FDA approval for the KRAS inhibitor Lumakras just one week ago, but there’s just too much to do. The company is instead looking to a new cohort from its pivotal trial, which is beginning to reveal the patients most likely to benefit from the drug formerly known as sotorasib. read more Sponsored by: The State of Maryland Prior to the pandemic, nearly a quarter of Maryland’s biopharm and medical tech companies focused on infectious diseases. As COVID-19 spread, dozens of Maryland companies joined the global response. read more By Annalee Armstrong Novartis rolled out results from two phase 2 trials for investigational kidney disease medicine iptacopan that showed stabilization of kidney function in one and the reduction of a key marker for kidney disease progression in the other. read more Sponsored By: Health Logic Health Logic Interactive is working on advanced technology called MATLOC that has the potential to revolutionize the Chronic Kidney Disease treatment space from the ground up. read more By Nick Paul Taylor Elevation Oncology has filed to raise $100 million in an IPO. The money will support development of an anti-HER3 antibody that failed multiple trials at Merrimack Pharmaceuticals before being picked up by Elevation and repositioned as a treatment for solid tumors harboring an NRG1 fusion. read more By Nick Paul Taylor Iksuda Therapeutics has raised $47 million to take a CD19-targeted antibody-drug conjugate (ADC) into the clinic. The British biotech has ceded a big head start to CD19 ADC leader ADC Therapeutics but thinks it can come from behind by delivering a best-in-class product. read more By Angus Liu A Swiss biotech suggests that one of its clinical candidates, currently in late-stage development for breast cancer, may also work as a COVID-19 treatment. The drug, called balixafortide, reduced viral load of the coronavirus that causes COVID, as well as COVID-related inflammation markers, in hamsters. read more By Conor Hale Currently available in the U.S. with a prescription, the Galleri test is meant to help screen people who may already have an elevated risk for cancer, such as adults over the age of 50. read more By Arlene Weintraub Alpine Immune Sciences turned heads when AbbVie formed a deal with the company for a lupus drug that inhibits the immune protein CD28. But the company is also pursuing a strategy for stimulating CD28 to improve the immune response to cancer—and it presented evidence at ASCO that its plan may be working. read more |  | Health Care Is Home Care From study drug administration to blood draws, Marken’s fully integrated home healthcare solutions make participation in clinical research as simple as possible for patients. Learn more. |
Resources Sponsored by: Clinical Ink For faster deployment, improved patient engagement, and better-quality data — go where your patients are. GO BYOD with Lunexis™ from Clinical Ink. Sponsored by SDG Group Discover how Ashfield Healthcare uses the power of data and analytics to enable pre-call planning, inform sales rep actions and drive higher market share for its target pharmaceutical products. Sponsored by: BBK Worldwide Create a more diverse and inclusive clinical trial enrollment and engagement environment by learning the barriers to participation and the strategies to overcome them. Sponsored by: Thermo Fisher Scientific Autologous cell and gene therapy workflows involve isolating cells from an individual, engineering the cells, expanding and concentrating them, and infusing them back into the patient. Optimized automation of certain steps of the workflow may decrease hands-on time and the cost of the cell manufacturing process. Sponsored By: Veeva Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials. Sponsored By: WCG Trifecta The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
